<code id='6118AD83EA'></code><style id='6118AD83EA'></style>
    • <acronym id='6118AD83EA'></acronym>
      <center id='6118AD83EA'><center id='6118AD83EA'><tfoot id='6118AD83EA'></tfoot></center><abbr id='6118AD83EA'><dir id='6118AD83EA'><tfoot id='6118AD83EA'></tfoot><noframes id='6118AD83EA'>

    • <optgroup id='6118AD83EA'><strike id='6118AD83EA'><sup id='6118AD83EA'></sup></strike><code id='6118AD83EA'></code></optgroup>
        1. <b id='6118AD83EA'><label id='6118AD83EA'><select id='6118AD83EA'><dt id='6118AD83EA'><span id='6118AD83EA'></span></dt></select></label></b><u id='6118AD83EA'></u>
          <i id='6118AD83EA'><strike id='6118AD83EA'><tt id='6118AD83EA'><pre id='6118AD83EA'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:4
          Mark Lennihan/AP

          Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

          The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

          advertisement

          Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Biden administration opens offers in Medicare drug price negotiations
          Biden administration opens offers in Medicare drug price negotiations

          ScottOlson/GettyImagesWASHINGTON —TheBidenadministrationismakingitsopeningofferstopharmaceuticalcomp

          read more
          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more

          New research casts further doubt on a common procedure used with IVF

          AdobeAcommoninvitrofertilizationprocedureofferedtopatientswiththepromiseofincreasingtheirlikelihoodo